SCHEMBL7942885

SCHEMBL7942885

Nc1ncccc1NCc1cccc(NC(=O)c2ccc(Cl)cc2Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 6/20 0.61
AURKA O14965 3/20 0.61
AURKB Q96GD4 3/20 0.61
RPS6KB1 P23443 2/20 0.61
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
KDR P35968 1/20 0.51
CES1 P23141 1/20 0.51
GAA P10253 1/20 0.49
GRM4 Q14833 1/20 0.48
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
TYK2 P29597 1/20 0.47
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7942897 0.87 JAK2 (0.51) BACE1AURKAAURKBRPS6KB1MEN1
SCHEMBL7944671 0.87 BACE1 (0.64) BACE1AURKAAURKBRPS6KB1MEN1
SCHEMBL7944661 0.86 BACE1 (0.71) BACE1AURKAAURKBRPS6KB1KDR
SCHEMBL7942210 0.85 BACE1 (0.62) BACE1AURKAAURKBRPS6KB1KDR
SCHEMBL7940477 0.84 MEN1 (0.46) BACE1AURKAAURKBRPS6KB1MEN1
SCHEMBL7942206 0.84 BACE1 (0.66) BACE1AURKAAURKBRPS6KB1KDR
SCHEMBL7940967 0.83 BACE1 (0.57) BACE1AURKAAURKBRPS6KB1MEN1
SCHEMBL7933421 0.81 BACE1 (0.62) BACE1AURKAAURKBRPS6KB1KDR
SCHEMBL7940722 0.81 BACE1 (0.76) BACE1AURKAAURKBRPS6KB1KDR
SCHEMBL7939891 0.80 BACE1 (0.56) BACE1AURKAAURKBRPS6KB1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885AURKA 3552/4885AURKB 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.